Dementia Friendly Lancaster Teepa Snow Event
AFTD volunteers Samantha Fuller and Frank Alvarez are hosting an information table at the Dementia Friendly Lancaster Workshop on August 21, 2024, from 8 AM – 4 PM, EST. Hosted by occupational therapist Teepa Snow, the workshop will provide attendees with a better understanding of what people with dementia are going through, how care partners and persons…
Read MoreCaring for Carol by Caring for Me
In Caring for Carol by Caring for Me, Anthony P. Mauro Sr. recounts the emotional journey of caring for his wife, Carol, through her battle with FTD. The memoir highlights the couple’s struggles with misdiagnosis, the profound losses brought on by this unique type of dementia, and Anthony’s personal growth in embracing life’s inevitable sorrows. This…
Read MoreAFTD Webinar: FTD and ALS — A Collaborative Approach to Diagnosis and Care
We know of several genes that can cause hereditary FTD, ALS, and ALS with FTD, with C9orf72 the most common. Yet genetics is not the complete story, as these conditions can appear without a known genetic cause. In this AFTD Healthcare Professional Webinar, neurologists from Massachusetts General Hospital who specialize in FTD and ALS discuss…
Read MoreAdvancing Hope: AFTD-ADDF Partnership Announces New Award in Drug Discovery Program
AFTD has partnered with the Alzheimer’s Drug Discovery Foundation (ADDF) since 2007 to support preclinical research on promising new drugs through the Accelerating Drug Discovery for FTD program. We are proud to announce Jeffrey Rothstein, MD, PhD, a professor of neurology and director of the Robert Packard Center for ALS Research at Johns Hopkins University,…
Read MoreViewpoints of FTD – Brain Donation
While there is currently no cure or approved treatments for FTD, increasing numbers of diagnostic tools and experimental treatments are entering the clinical trial phase of their development. A major contributor to this progress is the growing number of people diagnosed with FTD participating in research, including through brain donation. Not only does a donation…
Read MoreBringing Hope & Light to the Dementia Journey
AFTD volunteer Joni Ralph is hosting an event table at Bringing Hope & Light to the Dementia Journey at UW Stevens Point on August 6, 2024. The full day education conference provides insights for care partners, professionals, and people living with FTD and other dementias.
Read MoreAFTD Volunteer Receives “Visionary of the Year 2024” Award for 40 Years of Advocacy
AFTD volunteer Wanda Smith received Alzheimer’s San Diego’s Visionary of the Year 2024 award for her FTD advocacy and awareness-raising efforts, which date back to the 1980s. Smith’s journey began when her mother, Sara Bridges, started to experience difficulties at work. Suspecting Alzheimer’s, Smith turned to Dr. Robert Katzman, MD, of the nearby University of…
Read MoreFrontotemporal Degeneration (FTD): Symptoms, Diagnosis, Responses, Outcomes, Family Stories
AFTD Volunteers Bruce Lipman and Erica Heffernan will be hosting an informational session at the Evanston Public Library on July 2 from 6-7:30 PM, CDT to offer powerful, personal perspectives on FTD. During this session, Bruce will share his insights as a care partner and support group volunteer, while Erica will discuss her experiences as…
Read MoreAFTD Volunteer Speaks about Trading Career for New “Vocation” as Caregiver
Alma Valencia, an AFTD volunteer in California, shared the challenges, stresses, and “moments of joy” she experiences as her mother’s caregiver in an as-told-to essay published recently in Business Insider. Valencia says she relished her career as a technical designer in the fashion industry, but she stepped away in 2020 to care for her mother,…
Read MoreTransposon Therapeutics Receives Fast Track Designation for PSP Treatment
Biotechnology company Transposon Therapeutics announced on May 21 that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for an intervention developed to treat progressive supranuclear palsy (PSP), an FTD disorder that primarily affects movement. The designation was granted to TPN-101, an orally administered drug that targets LINE-1, a virus-like…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)